EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?

por Cansouline, Xavier, Lipan, Béatrice, Sizaret, Damien, Tallet, Anne, Vandier, Christophe, Carmier, Delphine, Legras, Antoine
Publicado 2022

1-year mortality in lung cancer in France according to key timepoints of care pathways

por Rivière, Axelle, Lecuyer, Anne Isabelle, Laurent, Emeline, Lefebvre, Carole, Lecomte, Thierry, Olivier, Elodie, Carmier, Delphine, Plantier, Laurent, Grammatico-Guillon, Leslie
Publicado 2022

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

por Herbreteau, Guillaume, Langlais, Alexandra, Greillier, Laurent, Audigier-Valette, Clarisse, Uwer, Lionel, Hureaux, José, Moro-Sibilot, Denis, Guisier, Florian, Carmier, Delphine, Madelaine, Jeannick, Otto, Josiane, Souquet, Pierre-Jean, Gounant, Valérie, Merle, Patrick, Molinier, Olivier, Renault, Aldo, Rabeau, Audrey, Morin, Franck, Denis, Marc G, Pujol, Jean-Louis
Publicado 2020